(Total Views: 288)
Posted On: 12/11/2017 4:54:08 PM
Post# of 72447
Well, a disappointing day for the stock but IPIX has always been a fickle girl.
I was pleased to hear Leo's responses to Cabel's questions. They gave good answers to questions many of us had. I was glad to hear about the placebo being a bit lower than normal. Our 36.8% certainly looks more impressive compared to 70% instead of the 60% our trial showed. Cutting the incidence of severe OM by 50% is an impressive feat but 38.7% will do for now.
I think we will be pleased with the secondary outcomes and a decent deal will be struck. Most importantly this is a big step forward for treatment of OM for a large percentage of cancer patients. We'll toast the IPIX team for advancing yet another drug through mid-stage trials. Thanks to all real investors lending their support as well.
Go IPIX!
I was pleased to hear Leo's responses to Cabel's questions. They gave good answers to questions many of us had. I was glad to hear about the placebo being a bit lower than normal. Our 36.8% certainly looks more impressive compared to 70% instead of the 60% our trial showed. Cutting the incidence of severe OM by 50% is an impressive feat but 38.7% will do for now.
I think we will be pleased with the secondary outcomes and a decent deal will be struck. Most importantly this is a big step forward for treatment of OM for a large percentage of cancer patients. We'll toast the IPIX team for advancing yet another drug through mid-stage trials. Thanks to all real investors lending their support as well.
Go IPIX!
(3)
(0)
All my posts are my own personal opinion and speculation. They should not be used as the basis for any investment decision. No, I am not Scottsmith.
